Skip to main content
SpringerLink
Log in

Preliminary Assessment Prior to Oocyte Cryopreservation

  • Chapter
  • First Online:
Preventing Age Related Fertility Loss

  • 691 Accesses

Abstract

It has been estimated that around 90% of primordial follicles are lost by the age of 30 years, which is an average age of women starting family in most western countries [1, 2]. This suggests most women start trying to conceive in a state of depleted ovarian reserve; consequently, in some this leads to infertility and childlessness. Therefore, availability of Fertility Preservation Services is emerging as a basic health necessity for some women. Owing to recent advances in techniques for oocyte vitrification an option of effective fertility preservation, long before women have made reproductive decisions, has become available. However due to a range of factors which include lack of societal acceptance, inadequate awareness among patients as well as health care professionals, the economic cost and the organisational challenges, Fertility Preservation services are not readily accessible.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Live births in England and Wales by characteristics of mother. Office of National Statistics. 2012.

    Google Scholar 

  2. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1):e8772.

    Article  PubMed  PubMed Central  Google Scholar 

  3. McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev. 2000;21(2):200–14.

    CAS  PubMed  Google Scholar 

  4. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod. 2012;27:594–608.

    Article  CAS  PubMed  Google Scholar 

  5. Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Familial concordance for age at natural menopause: results from the Breakthrough Generations Study. Menopause. 2011;18:956–61.

    Article  PubMed  Google Scholar 

  6. Biasoli I, Falorio S, Luminari S, Spector N, Federico M. Fertility in female survivors of Hodgkin’s lymphoma. Rev Bras Hematol Hemoter. 2012;34(1):48–53. doi:10.5581/1516-8484.20120014.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Seifer DB, Golub ET, Lambert-Messerlian G, Benning L, Anastos K, Watts H, Cohen MH, Karim R, Young MA, Minkoff H, and Greenblatt RM. Variations in serum Mullerian inhibiting substance between white, black and Hispanic women. Fertil Steril. 2009;92(5):1674–8.

    Google Scholar 

  8. Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF III. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril. 2007;87:101–6.

    Article  CAS  PubMed  Google Scholar 

  9. Krishnan M, Rustamov O, Mathur R, Roberts S, Fitzgerald C. The effect of the ethnicity on the ovarian reserve. British Fertility Society Annual Meeting; 2014.

    Google Scholar 

  10. Sahmay S, Usta T, Erel CT, Imamoğlu M, Kuuk M, Atakul N, Seyisoğlu H. Is there any correlation between amh and obesity in premenopausal women? Arch Gynecol Obstet. 2012;286(3):661–5.

    Google Scholar 

  11. Skałba P Cygal A, Madej P, Dabkowska-Huc A, Sikora J, Martirosian G, Romanik M, Olszanecka-Glinianowicz M. Is the plasma anti-Mullerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol. 2011;158:254–9.

    Google Scholar 

  12. Rustamov O, Krishnan M, Mathur R, Roberts S, Fitzgerald C. The effect of BMI on the ovarian reserve. British Fertility Society Annual Meeting; 2014.

    Google Scholar 

  13. Depmann M, Faddy MJ, van der Schouw YT, P. Peeters HM, Broer S, Kelsey TM, Nelson SM, Broekmans FJM. The relationship between variation in size of the primordial follicle pool and age at natural menopause. J Clin Endocrinol Metab. 2015;100(6):E845–51.

    Google Scholar 

  14. Durlinger AL, et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology. 1999;140(12):5789–96.

    Article  CAS  PubMed  Google Scholar 

  15. Durlinger AL, et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142(11):4891–9.

    Article  CAS  PubMed  Google Scholar 

  16. Kelsey TW, et al. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One. 2011;6(7):e22024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. Lancet. 1996;348(9039):1402–6.

    Article  CAS  PubMed  Google Scholar 

  18. van Kooij RJ, et al. Age-dependent decrease in embryo implantation rate after in vitro fertilization. Fertil Steril. 1996;66(5):769–75.

    Article  PubMed  Google Scholar 

  19. Broekmans FJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685–718.

    Article  CAS  PubMed  Google Scholar 

  20. Abdalla H, Thum MY. Repeated testing of basal FSH levels has no predictive value for IVF outcome in women with elevated basal FSH. Hum Reprod. 2006;21(1):171–4.

    Article  CAS  PubMed  Google Scholar 

  21. Rustamov O, Pemberton P, Roberts S, Smith A, Yates A, Patchava S, Nardo L. The reproducibility of serum AMH in subfertile women: within and between patient variability. Fertil Steril. March 2011.

    Google Scholar 

  22. Broekmans Frank JM, de Ziegler D, Howles Colin M, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil Steril. 2010;94:1044–51.

    Article  CAS  PubMed  Google Scholar 

  23. Jayaprakasan K, et al. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010a;93(3):855–64.

    Article  CAS  PubMed  Google Scholar 

  24. Jayaprakasan K, et al. The cohort of antral follicles measuring 2–6 mm reflects the quantitative status of ovarian reserve as assessed by serum levels of anti-Mullerian hormone and response to controlled ovarian stimulation. Fertil Steril. 2010b;94:1775–81.

    Article  CAS  PubMed  Google Scholar 

  25. Haadsma ML, Bukman A, Groen H, Roeloffzen EM, Groenewoud ER, Heineman MJ, et al. The number of small antral follicles (2–6 mm) determines the outcome of endocrine ovarian reserve tests in a subfertile population. Hum Reprod. 2007;22:1925–31.

    Article  CAS  PubMed  Google Scholar 

  26. Rustamov O, Krishnan M, MacDougall J, Prentice A, Roberts S, Fitzgerald S, Mathur R. Antral follicle count: assessment of the discriminatory power of AFC by evaluation of its within-patient and between-patient variability. In: 9th Biennial Conference of UK Fertility Societies; 2015.

    Google Scholar 

  27. Rustamov O, Smith A, Roberts SA, et al. Anti-Mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Hum Reprod. 2012;27:3085–91.

    Article  CAS  PubMed  Google Scholar 

  28. Yates AP, Rustamov O, Roberts SA, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod. 2011;26:2353–62.

    Article  CAS  PubMed  Google Scholar 

  29. Anderson RA. Pretreatmentserumanti-müllerianhormonepredicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011;96:1336–43.

    Article  CAS  PubMed  Google Scholar 

  30. Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011a;17(1):46–54.

    Article  CAS  PubMed  Google Scholar 

  31. Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-mullerianhormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011b;96:2532–9.

    Article  CAS  PubMed  Google Scholar 

  32. Hudson PL, Dougas L, Donahoe PK, et al. An immunoassay to detect human müllerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab. 1990;70:16–22.

    Article  CAS  PubMed  Google Scholar 

  33. Qin Y, Jiao X, Simpson JL, Chen ZJ. Genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update. 2015;21(6):787–808.

    Article  PubMed  PubMed Central  Google Scholar 

  34. American College of Obstetricians and Gynecologists Committee on Genetics. ACOG committee opinion No. 469: carrier screening for fragile X syndrome. Obstet Gynecol. 2010;116(4):1008–10.

    Article  Google Scholar 

  35. Strom CM, Crossley B, Redman JB, Buller A, Quan F, Peng M, McGinnis M, Fenwick RG Jr, Sun W. Molecular testing for Fragile X Syndrome: lessons learned from 119,232 tests performed in a clinical laboratory. Genet Med. 2007;9(1):46–51.

    Google Scholar 

  36. Edwards JG, Feldman G, Goldberg J, Gregg AR, Norton ME, Rose NC, Schneider A, Stoll K, Wapner R, Watson MS. Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine. Obstet Gynecol. 2015;125(3):653–62.

    Google Scholar 

  37. Henneman L, Borry P, Chokoshvili D, Cornel MC, van El CG, Forzano F, Hall A, Howard HC, Janssens S, Kayserili H, Lakeman P, Lucassen A, Metcalfe SA, Vidmar L, de Wert G, Dondorp WJ, Peterlin B. Responsible implementation of expanded carrier screening. Eur J Hum Genet. 2016;24(6):e1–12.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aberdeen Centre of Reproductive Medicine, University of Aberdeen, Aberdeen, UK

    O. Rustamov

  2. Queen’s Hospital, Barking Havering and Redbridge University Hospitals, Essex, UK

    S. K. Sunkara

Authors
  1. O. Rustamov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. K. Sunkara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Rustamov .

Editor information

Editors and Affiliations

  1. Centre for Reproductive Medicine, UZ Brussel, Brussels, Belgium

    Dominic Stoop

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Rustamov, O., Sunkara, S.K. (2018). Preliminary Assessment Prior to Oocyte Cryopreservation. In: Stoop, D. (eds) Preventing Age Related Fertility Loss. Springer, Cham. https://doi.org/10.1007/978-3-319-14857-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-14857-1_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-14856-4

  • Online ISBN: 978-3-319-14857-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation